Risk of serious infection with JAK inhibitors in immune-mediated inflammatory skin diseases: a meta-analysis of randomized clinical trials
Creators: name: Su, Xinhong
name: Ou, Yushan
name: Ruan, Shifan
name: Lv, Xiaoqing
name: Qin, Kun
name: Mao, Jing
name: Ji, Chao
Publisher: name: Taylor & Francis
Year: 2025
Subjects: subject: Space Science
subject: Medicine
subject: Microbiology
subject: FOS: Biological sciences
subject: Pharmacology
subject: Biotechnology
subject: Immunology
subject: FOS: Clinical medicine
subject: Cancer
subject: Mental Health
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Virology

description: Emerging research suggests that Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors may be associated with a higher risk of serious infection for patients with rheumatoid arthritis. However, there is no consensus on whether JAK inhibitors increase the risk of serious infection in patients with Immune-mediated inflammatory skin diseases (IMISDs). To ascertain the correlation between JAK inhibitor use and the risk of serious infection in patients with IMISDs. PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and registered Clinical Trials were searched up to June 1, 2024, using specific search terms related to JAK inhibitors and IMISDs. Randomized clinical trials (RCTs) comparing JAK inhibitors with a control group in patients with IMISDs were included. Studies focusing on cohort studies, case reports, case series, review articles, pooled analysis studies, post hoc analyses and topical JAK inhibitors were excluded. Data were extracted independently by two authors, focusing on serious infections defined according to each study’s criteria. Crude numbers for serious infections were pooled and underwent meta-analysis. We assessed the primary outcome regarding the occurrence of severe infections for each study. Thirty-two randomized clinical trials involving 11,917 patients were included. Serious infections were reported in 0.62% of patients receiving JAK inhibitors and 0.51% of controls. Meta-analysis found no significant increase in risk of serious infection (I<sup>2</sup>=0.00%, RR, 0.68; 95% CI, 0.43–1.07). Subgroup analyses revealed no significant heterogeneity based on condition (<i>p</i> = .56) or medication (<i>p</i> = .69). This meta-analysis demonstrates that JAK inhibitors do not significantly increase the risk of serious infections in IMISD patients compared to control treatments. These findings support the safety of JAK inhibitors in this population. Future research should focus on real-world evidence to further assess their risk-benefit profile in dermatological practice. This meta-analysis, encompassing 32 studies with 11,917 participants, found that JAK inhibitors were well tolerated and did not significantly increase the risk of serious infection in the treatment of IMISDs.Subgroup analyses confirmed consistent results across different JAK inhibitors and dermatological conditions.Pneumonia was the most commonly reported serious infection. This meta-analysis, encompassing 32 studies with 11,917 participants, found that JAK inhibitors were well tolerated and did not significantly increase the risk of serious infection in the treatment of IMISDs. Subgroup analyses confirmed consistent results across different JAK inhibitors and dermatological conditions. Pneumonia was the most commonly reported serious infection.